Licensed products drive YuhanㆍChong Kun Dang to success
Yuhan Corporation leads the way with BiktarvyㆍJardianceㆍVemlidy K-CabㆍProlia foster Chong Kun Dang Pharmaceutical with the support of Atozet
[Newsmp] Yuhan and Chong Kun Dang's licensed blockbusters are still holding their own.
In the third quarter, Yuhan's Trajenta, the company's largest licensed product, saw a slight decrease in sales, but still recorded its best quarterly sales of any product, with sales of nearly KRW 30 billion.
Biktarvy's quarterly sales exceeded KRW 20 billion, up 54.0% from the same period last year while Jardiance also achieved sales of over KRW 20 billion for the second consecutive quarter, with growth of nearly 30%.
Although Twynsta's growth rate slowed, it still maintained quarterly sales of over KRW 20 billion, and Glivec and Vemlidy also recorded double-digit growth rates, with sales of KRW 16 billion and KRW 14 billion.
Moreover, Rosuvamibe, one of Yuhan's own products, also recorded a growth rate of 22.0% in the third quarter, exceeding KRW 20 billion for the second consecutive quarter.
During the first nine months of 2023, five imported pharmaceuticals, including Trajenta KRW 78.9 billion, Jardiance KRW 63.7 billion, Twynsta KRW 61.4 billion, Viread KRW 57.3 billion, and Biktarvy KRW 53.4 billion, have each generated sales more than KRW 50 billion, and Rosuvamibe has achieved sales of KRW 58.2 billion, close to the KRW 60 billion mark.
In the meantime, Chong Kun Dang's K-Cab sales reached KRW 30 billion for two straight months, and Prolia sales also exceeded KRW 30 billion, up 28.2%.
Januvia series sales fell by more than 20% due to patent expiration, but still maintained sales of nearly KRW 30 billion. Gliatirin and Atozet also achieved sales of over KRW 20 billion, along with other major licensed products.
Chong Kun Dang's self-developed product Dilatrend saw its sales increase by 22.0% to KRW 17.7 billion, and Tacrobell, Imotun, and Telminuvo also posted sales of over KRW 10 billion.
Januvia was the top-selling product for the nine months, with cumulative sales of KRW 91.1 billion, followed by K-Cab with KRW 90.4 billion, Prolia with KRW 86 billion, Gliatirin with KRW 66.8 billion, and Atozet with KRW 65.4 billion, all achieving sales exceeding KRW 60 billion.